Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis

PloS One
Ting-Fang HeYuan Yuan

Abstract

The evolutionary changes in immune profiles of triple negative breast cancer (TNBC) are not well understood, although it is known that immune checkpoint inhibitors have diminished activity in heavily pre-treated TNBC patients. This study was designed to characterize immune profile changes of longitudinal tumor specimens by studying immune subsets of tumor infiltrating lymphocytes (TILs) in paired primary and metastatic TNBC in a cohort of "poor outcome" (relapsed within 5 years) patients. Immune profiles of TNBCs in a cohort of "good outcome" (no relapse within 5 years) patients were also analyzed. Immune subsets were characterized for CD4, CD8, FOXP3, CD20, CD33, and PD1 using immuno-fluorescence staining in stroma, tumor, and combined stroma and tumor tissue. TIL subsets in "good outcome" versus "poor outcome" patients were also analyzed. Compared with primary, metastatic TNBCs had significantly lower TILs by hematoxylin and eosin (H&E) staining. Stromal TILs (sTILs), but not tumoral TILs (tTILs) had significantly reduced cytotoxic CD8+ T cells (CTLs), PD1+ CTLs, and total PD1+ TILs in metastatic compared with matched primary TNBCs. Higher PD1+ CTLs, PD1+CD4+ helper T cells (PD1+TCONV) and all PD1+ T cells in sTILs, tTILs and...Continue Reading

References

Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carsten DenkertGunter von Minckwitz
Jan 10, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M V DieciF Andre
Sep 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R SalgadoUNKNOWN International TILs Working Group 2014
Nov 26, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G PruneriG Viale
May 4, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rita NandaLaurence Buisseret
Apr 2, 2017·The Breast : Official Journal of the European Society of Mastology·Giancarlo PruneriCarsten Denkert
Apr 21, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G PruneriG Viale
Jan 4, 2018·Oncoimmunology·Sylvain Simon, Nathalie Labarriere
Mar 17, 2018·Frontiers in Immunology·Linda ZianiJerome Thiery
Mar 22, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hope S RugoAntoinette R Tan
Mar 30, 2018·JAMA Oncology·Heather HampelUNKNOWN Ohio Colorectal Cancer Prevention Initiative Study Group
Aug 30, 2018·NPJ Breast Cancer·Kim R M BlenmanPeter P Lee
Mar 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M V DieciF Andre

❮ Previous
Next ❯

Citations

May 1, 2021·Genes·Felicitas MungenastRupert C Ecker
Jul 22, 2021·Journal of the National Cancer Institute·Sunil S BadveGiuseppe Viale
Sep 7, 2021·Breast Cancer Research and Treatment·Peter SavasSherene Loi

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
biopsies

Software Mentioned

InForm
Vectra
inForm ® Image Analysis

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.